Rodríguez-Carrio, J.; Alperi-López, M.; López, P.; Pérez-Álvarez, Á.I.; Gil-Serret, M.; Amigó, N.; Ulloa, C.; Benavente, L.; Ballina-García, F.J.; Suárez, A.
GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease. J. Clin. Med. 2020, 9, 2472.
https://doi.org/10.3390/jcm9082472
AMA Style
Rodríguez-Carrio J, Alperi-López M, López P, Pérez-Álvarez ÁI, Gil-Serret M, Amigó N, Ulloa C, Benavente L, Ballina-García FJ, Suárez A.
GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease. Journal of Clinical Medicine. 2020; 9(8):2472.
https://doi.org/10.3390/jcm9082472
Chicago/Turabian Style
Rodríguez-Carrio, Javier, Mercedes Alperi-López, Patricia López, Ángel I. Pérez-Álvarez, Miriam Gil-Serret, Núria Amigó, Catalina Ulloa, Lorena Benavente, Francisco J. Ballina-García, and Ana Suárez.
2020. "GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease" Journal of Clinical Medicine 9, no. 8: 2472.
https://doi.org/10.3390/jcm9082472
APA Style
Rodríguez-Carrio, J., Alperi-López, M., López, P., Pérez-Álvarez, Á. I., Gil-Serret, M., Amigó, N., Ulloa, C., Benavente, L., Ballina-García, F. J., & Suárez, A.
(2020). GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease. Journal of Clinical Medicine, 9(8), 2472.
https://doi.org/10.3390/jcm9082472
